Cutaneous T-cell Lymphoma Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG

Posted on
by

Cutaneous T-cell Lymphoma Market to Witness Upsurge in Growth During the Forecast Period (2023-2032), Examine DelveInsight | Innate Pharma, Galderma R&D, Kyowa Kirin, Citius Pharma, Soligenix, 4SC AG
“Cutaneous T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cutaneous T-cell Lymphoma, historical and forecasted epidemiology as well as the Cutaneous T-cell Lymphoma market trends in the 7MM.

DelveInsight’s “Cutaneous T-cell Lymphoma Market Insights, Epidemiology, and Market Forecast-2032″ report offers an in-depth understanding of the Cutaneous T-cell Lymphoma, historical and forecasted epidemiology as well as the Cutaneous T-cell Lymphoma market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

 

To Know in detail about the Cutaneous T-cell Lymphoma market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Cutaneous T-cell Lymphoma Market Forecast

 

Some of the key facts of the Cutaneous T-cell Lymphoma Market Report: 

  • The Cutaneous T-cell Lymphoma market size was valued approximately USD 500 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
  • As estimated, the largest market size for Cutaneous T-cell Lymphoma (CTCL) is observed in the United States in 2022, and it is expected to expand at a Compound Annual Growth Rate (CAGR) of approximately 3%.
  • In September 2023, Citius Pharmaceuticals disclosed receiving further instructions from the US FDA concerning their intended resubmission of the Company’s Biologics License Application (BLA) for LYMPHIR (denileukin diftitox) aimed at treating patients dealing with relapsed or refractory Cutaneous T-cell Lymphoma (CTCL) after undergoing at least one previous systemic therapy. Additionally, the company aims to finalize the activities required for addressing the Complete Response Letter (CRL) by the conclusion of the year and submit the revised application in early 2024.
  • In 2022, the collective number of new cases of Cutaneous T-cell Lymphoma (CTCL) across the seven major markets (7MM) was estimated to be around 5,000. Projections suggest a rise in this incident population during the forecast period.
  • In the EU4 countries and the UK, Germany reported the highest number of CTCL cases, followed by France. Spain consistently had the lowest number of cases compared to the other EU4 nations and the UK throughout the study period from 2020 to 2034.
  • In 2022, gender-specific cases of CTCL in the United States indicated around 2,000 cases for males and approximately 1,500 cases for females. Forecasts suggest a potential increase in these cases during the projected period.
  • Anticipated introductions of potential therapies such as SGX301 by Soligenix, I/ONTAK (E7777) by Citius Pharma, Remetinostat by Medivir AB, EQ101 by Equillium, ASTX660 by Astex Pharmaceuticals, and other treatments are expected to contribute to an expansion in the market size in the forthcoming years.
  • Key Cutaneous T-cell Lymphoma Companies: Citius Pharmaceuticals, Soligenix, 4SC AG, Innate Pharma, Galderma R&D, Kyowa Kirin, Inc, oligenix, Ligand Pharmaceuticals, Bausch Health Americas, Inc., BioCryst Pharmaceuticals, Novartis, Celgene, Soligenix, Pfizer, Bioniz Therapeutics, Eisai Inc., Merck Sharp & Dohme LLC, and others
  • Key Cutaneous T-cell Lymphoma Therapies: I/ONTAK, HyBryte, Resminostat, Lacutamab, CD11301, Mogamulizumab, Hypericin, ONTAK (denileukin difitox, DAB389IL-2), Bexarotene, Forodesine 200 mg, Panobinostat, romidepsin (depsipeptide, FK228), SGX301 (synthetic hypericin), Ritlecitinib, BNZ132-1-40, ONTAK Pembrolizumab, and others
  • According to the research conducted by Rangoonwala et al. in 2022, Mycosis Fungoides (MF) stands as the most prevalent subtype among Cutaneous T-cell Lymphomas (CTCLs), accounting for roughly 50% of all CTCL cases. The incidence rate of MF appears to be nearly twice as frequent in males, with individuals typically diagnosed at a median age between 55 and 60 years old.
  • The Cutaneous T-cell Lymphoma market is expected to surge due to the disease’s increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Cutaneous T-cell Lymphoma pipeline products will significantly revolutionize the Cutaneous T-cell Lymphoma market dynamics.

 

Cutaneous T-cell Lymphoma Overview

Cutaneous T-cell lymphoma (CTCL) refers to a group of non-Hodgkin lymphomas (cancers of the lymphatic system) that primarily affect the skin. CTCL arises from T lymphocytes, a type of white blood cell, and typically manifests as a slow-growing cancer starting in the skin.

 

Get a Free sample for the Cutaneous T-cell Lymphoma Market Forecast, Size & Share Analysis Report: 

https://www.delveinsight.com/report-store/cutaneous-t-cell-lymphoma-ctcl-market

 

Cutaneous T-cell Lymphoma Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

 

Cutaneous T-cell Lymphoma Epidemiology Segmentation:

The Cutaneous T-cell Lymphoma market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

  • Total Prevalence of Cutaneous T-cell Lymphoma
  • Prevalent Cases of Cutaneous T-cell Lymphoma by severity
  • Gender-specific Prevalence of Cutaneous T-cell Lymphoma
  • Diagnosed Cases of Episodic and Chronic Cutaneous T-cell Lymphoma

 

Download the report to understand which factors are driving Cutaneous T-cell Lymphoma epidemiology trends @ Cutaneous T-cell Lymphoma Epidemiology Forecast

 

Cutaneous T-cell Lymphoma Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Cutaneous T-cell Lymphoma market or expected to get launched during the study period. The analysis covers Cutaneous T-cell Lymphoma market uptake by drugs, patient uptake by therapies, and sales of each drug. 

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Cutaneous T-cell Lymphoma Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

 

Cutaneous T-cell Lymphoma Therapies and Key Companies

  • I/ONTAK: Citius Pharmaceuticals
  • HyBryte: Soligenix
  • Resminostat: 4SC AG
  • Lacutamab: Innate Pharma
  • CD11301: Galderma R&D
  • Mogamulizumab: Kyowa Kirin, In
  • Hypericin: oligenix
  • ONTAK (denileukin difitox, DAB389IL-2): Ligand Pharmaceuticals
  • Bexarotene: Bausch Health Americas, Inc.
  • Forodesine 200 mg: BioCryst Pharmaceuticals
  • Panobinostat: Novartis
  • romidepsin (depsipeptide, FK228): Celgene
  • SGX301 (synthetic hypericin): Soligenix
  • Ritlecitinib: Pfizer
  • BNZ132-1-40: Bioniz Therapeutics
  • ONTAK: Eisai Inc.
  • Pembrolizumab: Merck Sharp & Dohme LLC

 

Discover more about therapies set to grab major Cutaneous T-cell Lymphoma market share @ Cutaneous T-cell Lymphoma Treatment Landscape

 

Cutaneous T-cell Lymphoma Market Strengths

  • CTCL has an active pipeline as many pharmaceutical companies are working towards developing an effective and affordable therapy

 

Cutaneous T-cell Lymphoma Market Opportunities

  • The disease tends to show resistance to medications creating a need for a more efficacious drug; there are many competitors in the drug development space working on different classes of therapeutics. Therefore, therapy should stand out in terms of cost, efficacy, and other relevant parameters to create an impact on the market.

 

Scope of the Cutaneous T-cell Lymphoma Market Report

  • Study Period: 2020–2034
  • Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
  • Key Cutaneous T-cell Lymphoma Companies: Citius Pharmaceuticals, Soligenix, 4SC AG, Innate Pharma, Galderma R&D, Kyowa Kirin, Inc, oligenix, Ligand Pharmaceuticals, Bausch Health Americas, Inc., BioCryst Pharmaceuticals, Novartis, Celgene, Soligenix, Pfizer, Bioniz Therapeutics, Eisai Inc., Merck Sharp & Dohme LLC, and others
  • Key Cutaneous T-cell Lymphoma Therapies: I/ONTAK, HyBryte, Resminostat, Lacutamab, CD11301, Mogamulizumab, Hypericin, ONTAK (denileukin difitox, DAB389IL-2), Bexarotene, Forodesine 200 mg, Panobinostat, romidepsin (depsipeptide, FK228), SGX301 (synthetic hypericin), Ritlecitinib, BNZ132-1-40, ONTAK Pembrolizumab, and others
  • Cutaneous T-cell Lymphoma Therapeutic Assessment: Cutaneous T-cell Lymphoma current marketed and Cutaneous T-cell Lymphoma emerging therapies
  • Cutaneous T-cell Lymphoma Market Dynamics: Cutaneous T-cell Lymphoma market drivers and Cutaneous T-cell Lymphoma market barriers 
  • Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Cutaneous T-cell Lymphoma Unmet Needs, KOL’s views, Analyst’s views, Cutaneous T-cell Lymphoma Market Access and Reimbursement 

 

To know more about Cutaneous T-cell Lymphoma companies working in the treatment market, visit @ Cutaneous T-cell Lymphoma Clinical Trials and Therapeutic Assessment

 

Table of Contents 

1. Cutaneous T-cell Lymphoma Market Report Introduction

2. Executive Summary for Cutaneous T-cell Lymphoma

3. SWOT analysis of Cutaneous T-cell Lymphoma

4. Cutaneous T-cell Lymphoma Patient Share (%) Overview at a Glance

5. Cutaneous T-cell Lymphoma Market Overview at a Glance

6. Cutaneous T-cell Lymphoma Disease Background and Overview

7. Cutaneous T-cell Lymphoma Epidemiology and Patient Population

8. Country-Specific Patient Population of Cutaneous T-cell Lymphoma 

9. Cutaneous T-cell Lymphoma Current Treatment and Medical Practices

10. Cutaneous T-cell Lymphoma Unmet Needs

11. Cutaneous T-cell Lymphoma Emerging Therapies

12. Cutaneous T-cell Lymphoma Market Outlook

13. Country-Wise Cutaneous T-cell Lymphoma Market Analysis (2020–2034)

14. Cutaneous T-cell Lymphoma Market Access and Reimbursement of Therapies

15. Cutaneous T-cell Lymphoma Market Drivers

16. Cutaneous T-cell Lymphoma Market Barriers

17.  Cutaneous T-cell Lymphoma Appendix

18. Cutaneous T-cell Lymphoma Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

 

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email: Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/